BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. J Gastroenterol. 2004;39:34-40. [PMID: 14767732 DOI: 10.1007/s00535-003-1242-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106:1264-1271. [PMID: 21364549 DOI: 10.1038/ajg.2011.45] [Cited by in Crossref: 108] [Cited by in F6Publishing: 103] [Article Influence: 9.8] [Reference Citation Analysis]
2 Peng XM, Gu L, Huang YS, Ma HH, Xie QF, Li G, Gao ZL. Simultaneous detection of two major lamivudine-resistant mutants using competitively differentiated-PCR. J Virol Methods 2005;128:168-75. [PMID: 15950294 DOI: 10.1016/j.jviromet.2005.04.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
3 Mello FC, Souto FJ, Nabuco LC, Villela-Nogueira CA, Coelho HS, Franz HC, Saraiva JC, Virgolino HA, Motta-Castro AR, Melo MM. Hepatitis B virus genotypes circulating in Brazil: molecular characterization of genotype F isolates. BMC Microbiol. 2007;7:103. [PMID: 18036224 DOI: 10.1186/1471-2180-7-103] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 5.1] [Reference Citation Analysis]
4 Yang JH, Zhang H, Chen XB, Chen G, Wang X. Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol 2013; 19(24): 3861-3865 [PMID: 23840126 DOI: 10.3748/wjg.v19.i24.3861] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
5 Mao H, Wang H, Zhang D, Mao H, Zhao J, Shi J, Cui Z. Study of hepatitis B virus gene mutations with enzymatic colorimetry-based DNA microarray. Clinical Biochemistry 2006;39:67-73. [DOI: 10.1016/j.clinbiochem.2005.10.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
6 Yıldız O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yıldırmak T, Kantürk A, Tütüncü E, Group HBS. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol 2011; 17(45): 4987-4992 [PMID: 22174548 DOI: 10.3748/wjg.v17.i45.4987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
7 Vutien P, Trinh HN, Garcia RT, Nguyen HA, Levitt BS, Nguyen K, da Silveira E, Daugherty T, Ahmed A, Garcia G. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin Gastroenterol Hepatol. 2014;12:1363-1370. [PMID: 24342744 DOI: 10.1016/j.cgh.2013.11.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
8 Tsubota A. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection? J Gastroenterol Hepatol 2006;21:1769-71. [PMID: 17074012 DOI: 10.1111/j.1440-1746.2006.04768.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
9 Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006;44:1656-65. [DOI: 10.1002/hep.21422] [Cited by in Crossref: 270] [Cited by in F6Publishing: 239] [Article Influence: 16.9] [Reference Citation Analysis]
10 Huang ZM, Huang QW, Qin YQ, He YZ, Qin HJ, Zhou YN, Xu X, Huang MJ. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J Gastroenterol 2005; 11(6): 867-870 [PMID: 15682483 DOI: 10.3748/wjg.v11.i6.867] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
11 Huang ZM, Huang QW, Qin YQ, Huang CH, Qin HJ, Zhou YN, Xu X, Lu CL. Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population. World J Gastroenterol 2005; 11(41): 6525-6529 [PMID: 16425428 DOI: 10.3748/wjg.v11.i41.6525] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
12 Nguyen MH, Garcia RT, Trinh HN, Nguyen HA, Nguyen KK, Nguyen LH, Levitt B. Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naïve patients with chronic hepatitis B. Aliment Pharmacol Ther 2009;30:1150-8. [PMID: 19785624 DOI: 10.1111/j.1365-2036.2009.04151.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
13 Choi YM, Lee SY, Kim BJ. Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression. World J Gastroenterol 2018; 24(16): 1708-1724 [PMID: 29713126 DOI: 10.3748/wjg.v24.i16.1708] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
14 Caligiuri P, Cerruti R, Icardi G, Bruzzone B. Overview of hepatitis B virus mutations and their implications in the management of infection. World J Gastroenterol 2016; 22(1): 145-154 [PMID: 26755866 DOI: 10.3748/wjg.v22.i1.145] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 65] [Article Influence: 12.3] [Reference Citation Analysis]
15 Shen T, Yan XM. Hepatitis B virus genetic mutations and evolution in liver diseases. World J Gastroenterol 2014; 20(18): 5435-5441 [PMID: 24833874 DOI: 10.3748/wjg.v20.i18.5435] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
16 Peng XM, Gu L, Chen XJ, Li JG, Huang YS, Gao ZL. Optimization of competitively differentiated polymerase chain reaction in detection of HBV basal core promoter mutation. World J Gastroenterol 2005; 11(23): 3614-3618 [PMID: 15962387 DOI: 10.3748/wjg.v11.i23.3614] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Moehlen M, De Medina M, Hill M, Jeffers L, Schiff ER, Martin P. Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy. ISRN Hepatol 2013;2013:130384. [PMID: 27335823 DOI: 10.1155/2013/130384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Feng B, Wei L, Chen M, Wang L. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B. Microbiological Research 2008;163:487-92. [DOI: 10.1016/j.micres.2006.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
19 Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, Abacioglu YH. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol. 2006;21:1783-1788. [PMID: 17074014 DOI: 10.1111/j.1440-1746.2006.04567.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
20 Tan YW, Ge GH, Zhao W, Gan JH, Zhao Y, Niu ZL, Zhang DJ, Chen L, Yu XJ, Yang LJ. YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study. Braz J Infect Dis 2012;16:250-5. [PMID: 22729192 [PMID: 22729192 DOI: 10.1016/s1413-8670(12)70319-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]